These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 11034070)

  • 1. The viral and cellular microRNA targetome in lymphoblastoid cell lines.
    Skalsky RL; Corcoran DL; Gottwein E; Frank CL; Kang D; Hafner M; Nusbaum JD; Feederle R; Delecluse HJ; Luftig MA; Tuschl T; Ohler U; Cullen BR
    PLoS Pathog; 2012 Jan; 8(1):e1002484. PubMed ID: 22291592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectrum of Posttransplant Lymphoproliferations in NSG Mice and Their Association With EBV Infection After Engraftment of Pediatric Solid Tumors.
    Tillman H; Vogel P; Rogers T; Akers W; Rehg JE
    Vet Pathol; 2020 May; 57(3):445-456. PubMed ID: 32202225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCR signaling is required for posttransplant lymphoproliferative disease in immunodeficient mice receiving human B cells.
    Zhang TT; Cheng RY; Ott AR; Dahl NP; Suchland ER; Stoffers CM; Asher GD; Hou D; Thouvenel CD; Hill TF; Rawlings DJ; James RG
    Sci Transl Med; 2024 Apr; 16(742):eadh8846. PubMed ID: 38598616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Host genetic variants and gene expression patterns associated with Epstein-Barr virus copy number in lymphoblastoid cell lines.
    Houldcroft CJ; Petrova V; Liu JZ; Frampton D; Anderson CA; Gall A; Kellam P
    PLoS One; 2014; 9(10):e108384. PubMed ID: 25290448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting TfR1 with the ch128.1/IgG1 Antibody Inhibits EBV-driven Lymphomagenesis in Immunosuppressed Mice Bearing EBV
    Martínez LE; Daniels-Wells TR; Guo Y; Magpantay LI; Candelaria PV; Penichet ML; Martínez-Maza O; Epeldegui M
    Mol Cancer Ther; 2021 Sep; 20(9):1592-1602. PubMed ID: 34158342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Membrane-bound CD95 ligand modulates CD19-mediated B cell receptor signaling and EBV activation.
    Liu M; Huang C; Zhou X; Jiang C; Liu S; Gao Y; Kuang L; Lei Z; Jia R; Xu J; Legembre P; Liang X
    J Med Virol; 2024 Feb; 96(2):e29440. PubMed ID: 38299675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The inhibition of IRE1alpha/XBP1 axis prevents EBV-driven lymphomagenesis in NSG mice.
    Arena A; Romeo MA; Po A; Benedetti R; Gilardini Montani MS; Gonnella R; Santarelli R; Gaeta A; De Smaele E; Cirone M
    Microbiol Spectr; 2023 Dec; 11(6):e0263623. PubMed ID: 37882554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Primary immunodeficiency disease based on ITK mutation: report of a case].
    Li HY; Wu X; Yang FC; Li ZF; Li YC; Li YC
    Zhonghua Bing Li Xue Za Zhi; 2024 Jul; 53(7):744-746. PubMed ID: 38955711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Homozygous Six Base Pair Deletion Found in the NFATC2 Gene in a Patient with EBV-Associated Lymphoproliferation.
    Erman B; Bal SK; Aydoğmuş Ç; Ersoy GZ; Boztug K
    J Clin Immunol; 2024 Mar; 44(3):74. PubMed ID: 38427060
    [No Abstract]   [Full Text] [Related]  

  • 10. Collins PJ, Fox CP, George L, et al. Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells. Blood. 2021;137(2):203-215.
    Blood; 2022 Nov; 140(21):2306. PubMed ID: 36422856
    [No Abstract]   [Full Text] [Related]  

  • 11. The BCL-2 family protein inhibitor ABT-737 as an additional tool for the treatment of EBV-associated post-transplant lymphoproliferative disorders.
    Robert A; Pujals A; Favre L; Debernardi J; Wiels J
    Mol Oncol; 2020 Oct; 14(10):2520-2532. PubMed ID: 32623836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation.
    Ludwig LM; Nassin ML; Hadji A; LaBelle JL
    Front Pediatr; 2016; 4():135. PubMed ID: 28066751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of Bcl-2 and Bcl-xL by viral proteins as a possible cause of cancer.
    Alibek K; Irving S; Sautbayeva Z; Kakpenova A; Bekmurzayeva A; Baiken Y; Imangali N; Shaimerdenova M; Mektepbayeva D; Balabiyev A; Chinybayeva A
    Infect Agent Cancer; 2014; 9():44. PubMed ID: 25699089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice.
    Guinness ME; Kenney JL; Reiss M; Lacy J
    Cancer Res; 2000 Oct; 60(19):5354-8. PubMed ID: 11034070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
    Srimatkandada P; Loomis R; Carbone R; Srimatkandada S; Lacy J
    Eur J Haematol; 2008 May; 80(5):407-18. PubMed ID: 18221384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
    Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
    J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EBV-associated B- and T-cell posttransplant lymphoproliferative disorders following primary EBV infection in a kidney transplant recipient.
    Yin CC; Medeiros LJ; Abruzzo LV; Jones D; Farhood AI; Thomazy VA
    Am J Clin Pathol; 2005 Feb; 123(2):222-8. PubMed ID: 15842046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases.
    Cohen JI
    Semin Hematol; 2003 Apr; 40(2):116-23. PubMed ID: 12704588
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.